The FDA has granted a priority review designation to a new drug application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.
The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.
Japan's Pharmaceuticals and Medical Devices Agency has granted approval to frontline pembrolizumab as monotherapy and in combination with chemotherapy for the treatment of patients with recurrent or distant metastatic head and neck cancer.
Everett E. Vokes, MD, FASCO, who is a Giants of Cancer Care® recipient for Head and Neck Cancer, has been named the next president of ASCO for the 2021 to 2022 term.
The European Commission has approved pembrolizumab as a monotherapy or in combination with platinum and 5-FU chemotherapy for the frontline treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression (composite positive score ≥1) on their tumors.
Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic head and neck squamous cell carcinoma.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression on their tumors.
The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.
The question of what the accepted therapeutic strategies for de-intensification in low-risk, HPV-related oropharyngeal squamous cell carcinoma are will be debated in an upcoming discussion.
In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration cytology to determine the best course of treatment based on cytopathological result.